Last updated: February 25, 2026
What is Aggrastat’s Formulation and Excipient Composition?
Aggrastat (tirofiban) is a glycoprotein IIb/IIIa receptor antagonist used to prevent thrombosis in acute coronary syndrome (ACS). Its formulation requires specific excipients to ensure stability, bioavailability, and compatibility.
Core Formulation Details:
- Active Ingredient: Tirofiban hydrochloride
- Form: Intravenous (IV) infusion
- Typical Concentration: 250 µg/mL to 500 µg/mL
- Administration: Solution with saline or dextrose
Key Excipients:
- Sodium chloride: Maintains isotonicity.
- Hydrochloric acid and sodium hydroxide: Adjust pH to approximately 4.5–5.0.
- Stabilizers: Usually water for injection as solvent; limited use of stabilizers, as tirofiban is stable at recommended pH.
No proprietary excipients are specifically highlighted in the marketed formulation, though manufacturing processes often incorporate antioxidants or buffers to enhance stability.
Why Excipient Selection Matters for Aggrastat
Optimizing excipient strategy enhances drug stability, prolongs shelf life, reduces adverse reactions, and meets regulatory standards. It also affects manufacturing efficiency, cost, and commercial viability.
Key considerations include:
- Compatibility: Excipients must not react with tirofiban.
- Stability: Maintains peptide integrity over shelf life at various storage conditions.
- Compatibility with IV formulations: Prevents precipitation and ensures clear solutions.
Opportunities in Excipient Innovation
1. Stability-Enhancing Additives
Innovating antioxidants or buffering agents can extend shelf life, particularly for multi-dose vials. For example, adding antioxidants like ascorbic acid or tocopherols, though their compatibility with tirofiban must be tested.
2. Osmotic Adjusters
Alternative osmotic agents (e.g., mannitol) could improve compatibility with saline or dextrose solutions, particularly for stability during storage and infusion.
3. pH Buffers
Developing advanced buffering systems to maintain pH stability can enhance peptide stability, especially under variable storage conditions.
4. Customization for Delivery Systems
Formulating for other delivery methods (e.g., pre-filled syringes or infusion bags) may require excipients that improve solubility and compatibility with container materials.
Commercial Opportunities
Patent and Formulation Expansion
Patent protections on specific excipient combinations can provide exclusivity. Innovator companies may develop new formulations with improved stability, reduced excipient load, or novel delivery options.
Market Diversification
Expanding formulations to include freeze-dried or lyophilized powders for reconstitution can open new markets, especially in regions with limited cold chain logistics.
Regulatory Pathways
Developing excipient-based formulations aligned with global regulatory standards (e.g., US FDA, EMA) can facilitate faster approval and broader market access.
Strategic Partnerships
Collaborations with excipient suppliers can enable access to novel stabilizers or buffers, reducing costs and accelerating product development.
Cost Optimization
Ability to substitute high-cost excipients with cost-effective alternatives without compromising stability or efficacy allows for competitive pricing and expands access.
Regulatory and Manufacturing Considerations
- Compliance: Excipient changes must align with pharmacopoeial standards (USP, EP).
- Stability Data: Demonstrate compatibility over shelf life.
- Bioequivalence: Ensure no alteration in pharmacokinetic profile.
- Manufacturing: Scale-up must consider excipient sourcing and quality control.
Summary Table
| Aspect |
Details |
Opportunities |
| Excipients |
Sodium chloride, HCl, NaOH, water |
Formulation stability |
| Innovation |
Antioxidants, buffers, osmotic agents |
Shelf life extension |
| Commercial |
Patentable excipient combinations |
Market differentiation |
| Regulatory |
Must meet pharmacopeia standards |
Accelerated approvals |
| Cost |
Potential for excipient substitution |
Price competitiveness |
Key Takeaways
- Aggrastat formulations rely on simple excipients, primarily for pH and isotonicity.
- Innovation opportunities exist in stabilizer, buffer, and delivery technology development.
- Patent strategies surrounding excipient combinations can extend product lifecycle.
- Developing stable, convenient formulations suited for diverse delivery systems enhances market reach.
- Regulatory strategies must prioritize compatibility, stability, and compliance with global standards.
FAQs
1. Can excipient reformulation improve Aggrastat’s shelf life?
Yes. Incorporating stabilizers or buffering agents validated for compatibility can prolong stability.
2. Are there current patents covering excipient compositions for Aggrastat?
Patent landscapes include specific formulations and delivery methods, though primary patents focus on the active ingredient. Evaluating existing patents is necessary before developing new excipient blends.
3. What excipients are critical for IV formulations of peptides like tirofiban?
Isotonic agents (sodium chloride), pH adjusters (HCl, NaOH), and water for injection are standard; integrative stabilizers are less common due to peptide sensitivity.
4. How do excipient modifications impact regulatory approval?
Any change requires stability testing, demonstrating no impact on efficacy or safety and satisfying pharmacopoeial standards.
5. What markets could benefit from improved Aggrastat formulations?
Emerging markets with less robust cold chain infrastructure benefit from lyophilized or stable liquid formulations; advanced formulations could expand in developed markets with personalized dosing needs.
References
-
U.S. Food and Drug Administration. (2018). Guidance for Industry: Sterile Drug Products Produced by aseptic processing — Data integrity and quality systems. FDA.
-
European Medicines Agency. (2017). ICH Q10 Pharmaceutical Quality System. EMA.
-
U.S. Pharmacopoeia. (2022). USP General Chapter <1079> Good Reliability Practices for Repackaging Drug Products.
-
Zhang, Z., et al. (2019). Stability of peptide pharmaceuticals in aqueous solution. Journal of Pharmaceutical Sciences, 108(5), 1544–1552.
-
Johnson, R. (2016). Formulation strategies for peptide drugs. Advanced Drug Delivery Reviews, 102, 75-86.
